Cargando…

Efficacy of Omalizumab in Indolent Systemic Mastocytosis

BACKGROUND: Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slapnicar, Calum, Trinkaus, Martina, Hicks, Lisa, Vadas, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766258/ https://www.ncbi.nlm.nih.gov/pubmed/31637065 http://dx.doi.org/10.1155/2019/3787586

Ejemplares similares

Indolent systemic mastocytosis mimicking Crohn’s disease
por: Hadjivasilis, Alexandros, et al.
Publicado: (2019)

Indolent systemic mastocytosis in a patient with ileocolitis
por: Chrysakopoulos, Georgios, et al.
Publicado: (2014)

Delayed Diagnosis of Adult Indolent Systemic Mastocytosis
por: Mikkelsen, Carsten Sauer, et al.
Publicado: (2014)

Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab
por: Lieberoth, Sofie, et al.
Publicado: (2015)

An elusive case of systemic mastocytosis
por: Lee, JK, et al.
Publicado: (2010)

Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock
por: Chatterjee, Manidipam, et al.
Publicado: (2018)

Primary cicatricial alopecia associated with systemic indolent mastocytosis
por: Prasad, Sonya, et al.
Publicado: (2020)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications
por: Bossi, Grazia, et al.
Publicado: (2023)

Increasing evidence for omalizumab in the treatment of bullous pemphigoid
por: Lonowski, Sarah, et al.
Publicado: (2020)

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
por: Selcuk, Ali, et al.
Publicado: (2021)

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2023)

DNA methylation profile in patients with indolent systemic mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2021)

Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab
por: Collins, Jennifer, et al.
Publicado: (2012)

Pancreatic neuroendocrine tumor presenting in indolent systemic mastocytosis: A case report
por: Sacco, Keith, et al.
Publicado: (2020)

Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis
por: Liu, Taoming, et al.
Publicado: (2021)

Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis
por: Gülsen, Askin, et al.
Publicado: (2021)

Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature
por: Doan, Serge, et al.
Publicado: (2016)

Indolent systemic mastocytosis associated with light chain deposition disease
por: Sasaki, Kotaro, et al.
Publicado: (2012)

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis”
por: Moshref Razavi, Habib, et al.
Publicado: (2022)

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report
por: Alshurafa, Awni, et al.
Publicado: (2023)

Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches
por: Paiva, Marcelo L., et al.
Publicado: (2023)

Improvement in Hematology Interprofessional Care: Simulation With an Emphasis on Collaboration
por: Liederman, Zachary, et al.
Publicado: (2020)

Genome-Wide DNA Methylation and Gene Expression in Patients with Indolent Systemic Mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2023)

Effect of omalizumab for autoimmune progesterone dermatitis refractory to bilateral oophorectomy: a case report
por: Varghese, Akshay, et al.
Publicado: (2021)

Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome
por: Matito, Almudena, et al.
Publicado: (2013)

A rare manifestation of indolent systemic mastocytosis and its management during the coronavirus disease 2019 pandemic; educational lessons from Syria
por: Slaibi, Anas, et al.
Publicado: (2021)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Systemic mastocytosis – a diagnostic challenge
por: Lladó, Ana Cristina Amorim Oliveira Gaia, et al.
Publicado: (2014)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF(©)
por: Taylor, Fiona, et al.
Publicado: (2021)

Systemic mastocytosis: a rare cause of osteoporosis
por: Garla, Vishnu Vardhan, et al.
Publicado: (2019)

Mastocytosis and systemic sclerosis: a clinical association
por: Bagnato, Gianluca, et al.
Publicado: (2016)

Case Report: Treatment of systemic mastocytosis with sunitinib
por: Molderings, Gerhard J., et al.
Publicado: (2017)

Systemic Mastocytosis: A Mimicker of Reactive Arthritis
por: Nasrallah, Oussama G., et al.
Publicado: (2023)

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020)

Effect of Omalizumab for Autoimmune Progesterone Dermatitis Refractory to Bilateral Oophorectomy: A Case Report
por: Varghese, Akshay, et al.
Publicado: (2021)

Systemic Mastocytosis: A Rare Case of Increased Liver Stiffness
por: Adolf, Stefanie, et al.
Publicado: (2012)

Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
por: Padilla, Brad, et al.
Publicado: (2021)

The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity
por: Pyatilova, Polina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0edkcguqqd3ri6s3ac3umhkf6l